Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
Corcept (CORT) Beats on Q2 Earnings, Ups '23 Sales View
01:30pm, Thursday, 03'rd Aug 2023
Corcept's (CORT) second-quarter earnings and revenues beat estimates. The company gives updates on its pipelines and raises revenue guidance for 2023, reflecting strong performance of Korlym.
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
04:05pm, Wednesday, 26'th Jul 2023
MENLO PARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on
Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance
04:43pm, Thursday, 04'th May 2023
Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guidance for 2023.
Corcept Therapeutics Incorporated (CORT) Q1 2023 Earnings Call Transcript
11:43pm, Wednesday, 03'rd May 2023
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Offi
Corcept Therapeutics (CORT) Lags Q1 Earnings Estimates
07:02pm, Wednesday, 03'rd May 2023
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.20 per share a year ago.
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
02:32pm, Tuesday, 02'nd May 2023
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
04:05pm, Wednesday, 26'th Apr 2023
MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on
Why Is Corcept (CORT) Up 9.6% Since Last Earnings Report?
12:56pm, Thursday, 30'th Mar 2023
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Corcept's (CORT) Q4 Earnings and Revenues Miss Estimates
12:47pm, Wednesday, 01'st Mar 2023
Corcept Therapeutics' (CORT) fourth-quarter earnings and revenues lag estimates.
Corcept Therapeutics (CORT) Lags Q4 Earnings and Revenue Estimates
09:05pm, Tuesday, 28'th Feb 2023
Corcept (CORT) delivered earnings and revenue surprises of -39.13% and 0.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics Incorporated (CORT) Q4 2022 Earnings Call Transcript
07:59pm, Tuesday, 28'th Feb 2023
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q4 2022 Earnings Conference Call February 28, 2023 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Busines
MENLO PARK, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2022 financial results and provide a
Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe
12:48pm, Tuesday, 17'th Jan 2023
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies.
Our 7 Top Biotech Stock Picks for 2023
05:42pm, Friday, 09'th Dec 2022
If there's a silver lining regarding the coronavirus pandemic, it's that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow,
